Long-term remission of HIV-associated thrombocytopenia parallels ongoing suppression of viral replication.
作者信息
Zell S C, Peterson K
机构信息
Department of Internal Medicine, University of Nevada School of Medicine, Reno, USA.
出版信息
West J Med. 1997 Dec;167(6):433-5.
Abstract
摘要
相似文献
1
Long-term remission of HIV-associated thrombocytopenia parallels ongoing suppression of viral replication.
West J Med. 1997 Dec;167(6):433-5.
2
Therapeutic interventions in primary HIV infection.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S69-76.
3
[Immunologic thrombocytopenic purpura as a clinical manifestation of HIV infection].
Srp Arh Celok Lek. 1989 Jul-Aug;117(7-8):499-506.
4
Successful zidovudine therapy for HIV-related severe thrombocytopenia. Report of a sustained remission.
Acta Haematol. 1990;83(2):86-8. doi: 10.1159/000205174.
5
Suppression of hepatitis C virus replication is maintained long term following HAART therapy, in an individual with HCV/HIV co-infection.
Antivir Ther. 2004 Feb;9(1):139-42.
6
Superior effect of intravenous anti-D compared with IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison.
Am J Hematol. 2007 May;82(5):335-41. doi: 10.1002/ajh.20813.
7
[Acquired amegakaryocytic thrombocytopenic purpura treated with intravenous immunoglobulins].
Ann Med Interne (Paris). 2000 May;151(3):223-6.
8
Spinal epidural lipomatosis in a human immunodeficiency virus-positive patient receiving steroids and protease inhibitor therapy.
Clin Infect Dis. 2001 Mar 1;32(5):E90-1. doi: 10.1086/319209. Epub 2001 Feb 20.
9
10
[Early antiretroviral combination therapy--standard today and tomorrow].
Dtsch Med Wochenschr. 1997 Mar 14;122(11 Suppl):1-4.
引用本文的文献
1
Profile of HIV-Infected Hispanics with Pancytopenia.
Int J Environ Res Public Health. 2015 Dec 22;13(1):ijerph13010038. doi: 10.3390/ijerph13010038.
2
HIV and SIV Associated Thrombocytopenia: An Expanding Role for Platelets in the Pathogenesis of HIV.
Drug Discov Today Dis Mech. 2011 Summer;8(1-2):e25-e32. doi: 10.1016/j.ddmec.2011.10.001. Epub 2011 Nov 9.
本文引用的文献
1
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
JAMA. 1997 Jun 25;277(24):1962-9.
2
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.
JAMA. 1996 Jul 10;276(2):146-54.
3
Association of autoantibodies against platelet glycoproteins Ib/IX and IIb/IIIa, and platelet-reactive anti-HIV antibodies in thrombocytopenic narcotic addicts.
Br J Haematol. 1996 May;93(2):464-71. doi: 10.1046/j.1365-2141.1996.00502.x.
4
Impaired survival of bone marrow GPIIb/IIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia.
Br J Haematol. 1996 Mar;92(3):711-7. doi: 10.1046/j.1365-2141.1996.367904.x.
5
Managing HIV. Part 5: Treating secondary outcomes. 5.12 HIV and haematological disease.
Med J Aust. 1996 Apr 15;164(8):487-8.
6
Triple combinations: present and future.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S77-82.
7
Combination therapy from a clinician's perspective.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S62-8.
8
Individualization of therapy using viral markers.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S41-6.
9
Measuring viral load in the clinical setting.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S34-40.
10
Rapid screening of antiretroviral combinations.
J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10 Suppl 1:S24-7.
Zotero 插件